(Q30910296)

27 June 2017

1 reference

title

Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data (English)

1 reference

27 June 2017

0 references

François L Reboul

1

1 reference

27 June 2017

publication date

1 February 2004

1 reference

Hematology / Oncology Clinics of North America

27 June 2017

published in

1 reference

27 June 2017

volume

18

1 reference

27 June 2017

issue

1

1 reference

27 June 2017

page(s)

41-53

1 reference

A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-sm

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

Role of radiotherapy in combined modality treatment of locally advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

Radiation sensitization of bacterial spores by cis-dichlorodiammineplatinum(II)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

A review of platinum complex biochemistry suggests a rationale for combined platinum-radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

Radiation and platinum drug interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

Cisplatin and radiation: interaction probabilities and therapeutic possibilities

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

Modification of the effects of continuous low dose rate irradiation by concurrent chemotherapy infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

Radiation therapy with concomitant continuous infusion cisplatin for unresectable nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

Carboplatin as a potentiator of radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

Irradiation enhances cellular uptake of carboplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

The interaction of etoposide with radiation: variation in cytotoxicity with the sequence of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160).

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

Concurrent radiochemotherapy for patients with stage III non-small-cell lung cancer (NSCLC): long-term results of a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

A phase II study of concurrent accelerated hyperfractionated radiotherapy and carboplatin/oral etoposide for elderly patients with stage III non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

Twice daily irradiation increases locoregional control in patients with medically inoperable or surgically unresectable stage II-IIIB non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900138-2

7 January 2021

10.1016/S0889-8588(03)00138-2

Identifiers

DOI

1 reference

27 June 2017

1 reference